In a recent study, approximately 66.7% of patients with breast cancer receiving taxanes monotherapy recovered from CIA, and more than 70% restored E2 and FSH after two years after treatment (13), which suggested that ovarian damage induced by taxanes may be temporary. Here, BRD2 is linked to breast carcinoma.